Methylene Blue Injection for Nonneoplastic Epithelial Disorders of Vulva

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

118 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-10-01

Study Completion Date

2019-10-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to demonstrate the safety and effectiveness of mixed methylene blue compound Injection for the treatment of nonneoplastic epithelial disorders（NNEDS） of vulva.

NNEDS of skin and mucosa of vulva refer to a group of chronic diseases including squamous hyperplasia and lichen sclerosus, which mainly cause vulvar itching and hypopigmentation. Usually the itching is severe may influence social activities and sleep. In addition, NNEDS cause scarring of the vulva which may cause significant sexual dysfunction or pain. The reasons for NNEDs are not clear and the methods of treatment are diverse. The current treatments are primarily local drug (e.g. steroid, calcineurin inhibitors, immunosuppressive agents ), surgical treatments, laser or photodynamic therapy, and the "gold standard" treatment for lichen sclerosus is potent steroids creams. However, all the treatments are not good enough, and the diseases often recur and severely affect women's quality of life. So the investigators reviewed plenty of literatures, and found some authors used single intradermal 1% methylene blue injection for intractable idiopathic pruritus ani and the effect was good. As a preliminary experiment, the investigators used intradermal mixed methylene blue compound injection for a NNEDs patient in the year of 2012, the itching of the patient stopped immediately and the color of the vulva recovered 6 months later. The patient keeps healthy till now. And from then on, the investigators designed this study and to verify the effect and complications of intradermal mixed methylene blue compound injection for the treatment of NNEDS. So far, there is no similar study reported internationally.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nonneoplastic Epithelial Disorders of Vulva and High Intensity Focused Ultrasound

NCT02890277

Vulva Intraepithelial Nonneoplastic

UNKNOWN NA

A Comparative Study on the Efficacy of AI Temperature-controlled Radiofrequency Technology and Electrical Stimulation in the Treatment of Vulvar Leukoplakia

NCT05250466

Vulvar Lichen Sclerosus

UNKNOWN NA

Gynecologic Extramammary Paget's Disease

NCT03564483

Extramammary Paget's Disease Extramammary Paget Disease Paget Disease, Extramammary +6 more

RECRUITING

Topical 5% Imiquimod Cream for Vulvar Paget's Disease

NCT02385188

Paget Disease, Extramammary

COMPLETED PHASE3

A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis

NCT07312604

Tinea Corporis Tinea Cruris

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.

In this study，the investigators used methylene blue compound injection intradermally to treat NNEDs patients. Patients with a diagnosis of biopsy proven NNEDs from Maternal and Child Health Hospital of Hubei Province (China) between October 2013 to October 2016 were recruited. Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department. Ages, itching scores, percentage of hypopigmented skin, and recurrences were recorded through inquiry and physical examination before and after treatment. Side effects (such as edema, fever and vulva pain) were also recorded. All women were followed up 1, 3, 6, 12 months after treatment, which included inquiry and physical examination.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Nonneoplastic Epithelial Disorders of Vulva

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Pations with nonneoplastic epithelial disorders（NNEDS） of vulva.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

treatment group

Methylene blue compound injection are mixed by Methylene Blue injection, Dexamethasone powder-injection, Ropivacaine injection and Normal saline injection. Each individual component can help in a very wide range of medical conditions without serious side effects.

Every patient received intradermal mixed methylene blue compound injection twice. All patients were observed during the hospitalization at the first injection, and two weeks later they received the second injection at the outpatient department.

Group Type EXPERIMENTAL

mixed methylene blue compound injection

Intervention Type DRUG

Every patient received intradermal mixed methylene blue compound injection twice.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

mixed methylene blue compound injection

Every patient received intradermal mixed methylene blue compound injection twice.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with clinically and biopsy confirmed non-neoplasia epithelial disorders of skin and mucosa of vulva.
* Patient must have a score of 5 or greater in the itching score table before treatment and the itching must last at least 6 months.

Exclusion Criteria

* Patients with vulvovaginal or other gynecological trauma, acute inflammatory diseases and other acute illness
* Patients have been treated with any kind of topical therapy at the vulva within 12 weeks prior to participation in the study
* Patients with other serious diseases (e.g. liver or kidney diseases) that need immediate treatment
* Patients with atypical vulvar hyperplasia or vulvar cancer confirmed by biopsy

Minimum Eligible Age

18 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes